vs
Mativ Holdings, Inc.(MATV)とPediatrix Medical Group, Inc.(MD)の財務データ比較。上の社名をクリックして会社を切り替えられます
Pediatrix Medical Group, Inc.の直近四半期売上が大きい($493.8M vs $463.1M、Mativ Holdings, Inc.の約1.1倍)。Mativ Holdings, Inc.の純利益率が高く(21.8% vs 6.8%、差は14.9%)。Mativ Holdings, Inc.の前年同期比売上増加率が高い(1.0% vs -1.7%)。過去8四半期でPediatrix Medical Group, Inc.の売上複合成長率が高い(-0.1% vs -3.8%)
Mativ Holdings, Inc.は世界的な特殊材料メーカーで、高性能先端ポリマー、不織布、ろ過ソリューション、機能性コーティング材料を製造しています。医療、産業、消費財、航空宇宙、エネルギー分野に顧客を持ち、北米、欧州、アジア太平洋地域で事業を展開しています。
Pediatrix Medical Group, Inc.は米国を代表する専門医療サービスプロバイダーで、母胎医療、新生児科、小児心臓病学などの小児亜専門を中心に事業を展開し、米国全土の医療機関と提携して女性、新生児、子どもに根拠に基づく質の高い医療を提供しています。
MATV vs MD — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | ||
|---|---|---|
| 売上 | $463.1M | $493.8M |
| 純利益 | $100.8M | $33.7M |
| 粗利率 | 18.8% | — |
| 営業利益率 | 2.2% | 9.9% |
| 純利益率 | 21.8% | 6.8% |
| 売上前年比 | 1.0% | -1.7% |
| 純利益前年比 | 6620.0% | 10.5% |
| EPS(希薄化後) | $1.87 | $0.40 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $463.1M | $493.8M | ||
| Q3 25 | $513.7M | $492.9M | ||
| Q2 25 | $525.4M | $468.8M | ||
| Q1 25 | $484.8M | $458.4M | ||
| Q4 24 | $458.6M | $502.4M | ||
| Q3 24 | $498.5M | $511.2M | ||
| Q2 24 | $523.8M | $504.3M | ||
| Q1 24 | $500.2M | $495.1M |
| Q4 25 | $100.8M | $33.7M | ||
| Q3 25 | $-3.2M | $71.7M | ||
| Q2 25 | $-9.5M | $39.3M | ||
| Q1 25 | $-425.5M | $20.7M | ||
| Q4 24 | $1.5M | $30.5M | ||
| Q3 24 | $-20.8M | $19.4M | ||
| Q2 24 | $-1.4M | $-153.0M | ||
| Q1 24 | $-28.0M | $4.0M |
| Q4 25 | 18.8% | — | ||
| Q3 25 | 19.3% | — | ||
| Q2 25 | 19.7% | — | ||
| Q1 25 | 15.0% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 18.8% | — | ||
| Q2 24 | 20.8% | — | ||
| Q1 24 | 16.8% | — |
| Q4 25 | 2.2% | 9.9% | ||
| Q3 25 | 3.1% | 13.8% | ||
| Q2 25 | 3.8% | 12.8% | ||
| Q1 25 | -88.8% | 7.0% | ||
| Q4 24 | 0.6% | 7.8% | ||
| Q3 24 | 1.4% | 6.6% | ||
| Q2 24 | 2.0% | -31.3% | ||
| Q1 24 | -2.8% | 3.2% |
| Q4 25 | 21.8% | 6.8% | ||
| Q3 25 | -0.6% | 14.5% | ||
| Q2 25 | -1.8% | 8.4% | ||
| Q1 25 | -87.8% | 4.5% | ||
| Q4 24 | 0.3% | 6.1% | ||
| Q3 24 | -4.2% | 3.8% | ||
| Q2 24 | -0.3% | -30.3% | ||
| Q1 24 | -5.6% | 0.8% |
| Q4 25 | $1.87 | $0.40 | ||
| Q3 25 | $-0.06 | $0.84 | ||
| Q2 25 | $-0.18 | $0.46 | ||
| Q1 25 | $-7.82 | $0.24 | ||
| Q4 24 | $0.03 | $0.37 | ||
| Q3 24 | $-0.38 | $0.23 | ||
| Q2 24 | $-0.03 | $-1.84 | ||
| Q1 24 | $-0.52 | $0.05 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $84.2M | $375.2M |
| 総負債低いほど良い | $1.0B | $570.5M |
| 株主資本純資産 | $498.7M | $865.9M |
| 総資産 | $2.1B | $2.2B |
| 負債/資本比率低いほどレバレッジが低い | 2.07× | 0.66× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $84.2M | $375.2M | ||
| Q3 25 | $97.1M | $340.1M | ||
| Q2 25 | $95.6M | $224.7M | ||
| Q1 25 | $84.0M | $99.0M | ||
| Q4 24 | $94.3M | $229.9M | ||
| Q3 24 | $162.2M | $103.8M | ||
| Q2 24 | $133.4M | $19.4M | ||
| Q1 24 | $128.9M | $8.0M |
| Q4 25 | $1.0B | $570.5M | ||
| Q3 25 | $1.0B | $577.2M | ||
| Q2 25 | $1.1B | $583.9M | ||
| Q1 25 | $1.1B | $590.5M | ||
| Q4 24 | $1.1B | $597.1M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $498.7M | $865.9M | ||
| Q3 25 | $397.4M | $890.7M | ||
| Q2 25 | $416.6M | $833.8M | ||
| Q1 25 | $428.2M | $789.2M | ||
| Q4 24 | $858.5M | $764.9M | ||
| Q3 24 | $882.3M | $732.5M | ||
| Q2 24 | $898.0M | $706.5M | ||
| Q1 24 | $906.9M | $856.2M |
| Q4 25 | $2.1B | $2.2B | ||
| Q3 25 | $2.0B | $2.2B | ||
| Q2 25 | $2.1B | $2.1B | ||
| Q1 25 | $2.1B | $2.0B | ||
| Q4 24 | $2.4B | $2.2B | ||
| Q3 24 | $2.6B | $2.1B | ||
| Q2 24 | $2.6B | $2.0B | ||
| Q1 24 | $2.7B | $2.2B |
| Q4 25 | 2.07× | 0.66× | ||
| Q3 25 | 2.63× | 0.65× | ||
| Q2 25 | 2.66× | 0.70× | ||
| Q1 25 | 2.67× | 0.75× | ||
| Q4 24 | 1.30× | 0.78× | ||
| Q3 24 | 1.32× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | 1.30× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $19.3M | $114.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $8.0M | — |
| FCFマージンFCF / 売上 | 1.7% | — |
| 設備投資強度設備投資 / 売上 | 2.4% | — |
| キャッシュ転換率営業CF / 純利益 | 0.19× | 3.39× |
| 直近12ヶ月FCF直近4四半期 | $93.8M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $19.3M | $114.1M | ||
| Q3 25 | $72.8M | $137.3M | ||
| Q2 25 | $57.6M | $137.2M | ||
| Q1 25 | $-15.9M | $-117.5M | ||
| Q4 24 | $24.1M | $133.0M | ||
| Q3 24 | $37.6M | $91.8M | ||
| Q2 24 | $46.1M | $107.0M | ||
| Q1 24 | $-13.0M | $-125.2M |
| Q4 25 | $8.0M | — | ||
| Q3 25 | $66.7M | — | ||
| Q2 25 | $48.9M | — | ||
| Q1 25 | $-29.8M | — | ||
| Q4 24 | $2.0M | — | ||
| Q3 24 | $25.5M | — | ||
| Q2 24 | $37.4M | — | ||
| Q1 24 | $-25.1M | — |
| Q4 25 | 1.7% | — | ||
| Q3 25 | 13.0% | — | ||
| Q2 25 | 9.3% | — | ||
| Q1 25 | -6.1% | — | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | 5.1% | — | ||
| Q2 24 | 7.1% | — | ||
| Q1 24 | -5.0% | — |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 2.4% | — |
| Q4 25 | 0.19× | 3.39× | ||
| Q3 25 | — | 1.91× | ||
| Q2 25 | — | 3.49× | ||
| Q1 25 | — | -5.66× | ||
| Q4 24 | 16.07× | 4.36× | ||
| Q3 24 | — | 4.72× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -31.03× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MATV
| Other | $208.7M | 45% |
| SAS Segment | $157.4M | 34% |
| FAM Segment | $97.0M | 21% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |